Wyeth Redux diet drug settlements
Executive Summary"Fen-phen" intermediate and back-end opt-out claims filed in conjunction with Redux diet drug settlement total 90,000 as of May 3 deadline, Wyeth says May 15. National settlement trust has also logged more than 61,000 "matrix" claims, in which patients allege significant heart valve disease. "Only a fraction of the actual claim forms submitted will result in a payment," CFO Ken Martin tells analysts. Wyeth has approximately $1.8 bil. in reserves, in addition to $600 mil. in national trust; the company has recorded $14.6 bil. in litigation-related charges to date...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.